At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment of 2019-nCoV pneumonia by studying the efficacy of abidol hydrochloride, oseltamivir and lopinavir/ritonavir in the treatment of 2019-nCoV viral pneumonia, and to explore effective antiviral drugs for new coronavirus. To provide reliable evidence-based medicine basis for the treatment of viral pneumonia caused by new coronavirus infection.
Drug: Abidol hydrochloride
Abidol hydrochloride (0.2g once, 3 times a day,2 weeks)was added on the basis of group I.
Drug: Oseltamivir
Oseltamivir(75mg once, twice a day,2 weeks) was added on the basis of group I.
Drug: Lopinavir/ritonavir
Lopinavir/ritonavir (500mg once, twice a day,2 weeks)was added on the basis of group I.
Inclusion Criteria:
1. 2019-nCoV nucleic acid test was positive.
2. CT of the lung conformed to the manifestation of viral pneumonia.
Exclusion Criteria:
1. Patients who meet any of the contraindications in the experimental drug labeling
2. Patients who do not want to participate in this clinical study
Department and Institute of Infectious Disease
Wuhan, Hubei, China
Investigator: Qin Ning, professor
qning@vip.sina.com
Qing Ning, Professor
+8613971521450
qning@vip.sina.com
Meifang Han, Professor
+8613986093605
mfhan@foxmail.com